GLUCOCORTICOID RECEPTOR AGONIST COMPRISING NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE CONTAINING PHENYL GROUP HAVING SULFONIC ACID ESTER STRUCTURE INTRODUCED THEREIN AS SUBSTITUENT
申请人:Santen Pharmaceutical Co., Ltd
公开号:EP2327699A1
公开(公告)日:2011-06-01
The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). R1 represents a group represented by general formula (2a), (3a), (4a) or (5a); R2 represents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; R3 represents a lower alkyl group; R4, R5, R6 or R7 represent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2.
该对象旨在发现一种新型的药理活性,该活性来自一种新型的1,2,3,4-四氢喹喔啉衍生物,其中含有一个苯基,其上引入了磺酸酯结构。通式(1)表示的化合物或其盐可用作糖皮质激素受体激动剂,特别是作为治疗剂,用于一些被认为对糖皮质激素受体激动剂(例如类固醇)有效的疾病,例如炎症性骨关节疾病,炎症性眼科疾病(眼睛前段或后段的炎症性眼科疾病)。其中,R1表示通式(2a)、(3a)、(4a)或(5a)表示的基团;R2表示可能有取代基的较低烷基基团、可能有取代基的较低环烷基基团等;R3表示较低烷基基团;R4、R5、R6或R7表示卤素原子、可能有取代基的较低烷基基团、羟基、可能有取代基的较低烷氧基团等;m、n、p或q表示0、1或2的数字。